August 2026

Oncology pharmacists unite care teams like World Cup midfielders—coordinating safe care and supporting patients through hope, setbacks, and dignity.

Residency ranking often shifts from structured metrics to “fit” and vibes, risking bias toward familiarity; refocus decisions on evidence, values, and potential.

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

Revumenib and ziftomenib in NPM1-mutated AML: practical guidance on differentiation syndrome, QTc monitoring, and drug interactions.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

Radiopharmaceuticals force oncology pharmacists to master safety, timing, waste, and costs—see how departments build radioactive therapy workflows.